The Society for Immunotherapy of Cancer (SITC) Cancer Immunotherapy Guidelines initiative began in 2010 when a group of researchers and clinicians united to address the lack of formal guidance on the use of cancer immunotherapy.
Each consensus statement is developed by an expert Task Force in a particular disease setting and follows the Academy of Medicine’s (formerly Institute of Medicine) Standards for Developing Trustworthy Clinical Practice Guidelines. One aspect of this systematic process is a 30-day open comment period, which allows all SITC members to provide feedback on the current draft of the consensus statement, prior to submission.
Being the leading member-driven organization dedicated to advancing the science and clinical application of cancer immunotherapy, SITC relies on this feedback to ensure the guidelines address all relevant issues and meet the goals of this initiative.
Please see below for currently open Member Comment periods. If you are not a SITC member and would like to participate, join SITC or renew your membership.
A Member Comment period is currently open for SITC members on the consensus statement for the Cancer Immunotherapy Guidelines, non-small cell lung cancer. The period opened Monday, March 19, with comments due by Midnight EST on April 18, 2018.
To read the current draft of the manuscript and submit comments:
The number of Cancer Immunotherapy Guidelines published by SITC via the Journal for ImmunoTherapy of Cancer (JITC) continues to grow. Click the links below to view previously published guidelines in different disease states:
Click the following links to learn more about the leaders charged with creating the SITC Guidelines:
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com